BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22824479)

  • 1. A myriad of pathways to NASH.
    Larrain S; Rinella ME
    Clin Liver Dis; 2012 Aug; 16(3):525-48. PubMed ID: 22824479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
    Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
    J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J; Torok N
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving trends in nonalcoholic fatty liver disease.
    Delgado JS
    Eur J Intern Med; 2008 Mar; 19(2):75-82. PubMed ID: 18249301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.
    Willner IR; Waters B; Patil SR; Reuben A; Morelli J; Riely CA
    Am J Gastroenterol; 2001 Oct; 96(10):2957-61. PubMed ID: 11693332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced steatohepatitis.
    Stravitz RT; Sanyal AJ
    Clin Liver Dis; 2003 May; 7(2):435-51. PubMed ID: 12879993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
    Tiniakos DG
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):643-50. PubMed ID: 19478676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH.
    Koike K; Moriya K
    J Gastroenterol; 2005 Apr; 40(4):329-36. PubMed ID: 15868369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of metabolic syndrome in non-diabetic and non-cirrhotic patients with non-alcoholic steatohepatitis.
    Amarapurkar DN; Patel ND
    Trop Gastroenterol; 2004; 25(3):125-9. PubMed ID: 15682659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease and lipids.
    Wierzbicki AS; Oben J
    Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced hepatic steatosis.
    Amacher DE; Chalasani N
    Semin Liver Dis; 2014 May; 34(2):205-14. PubMed ID: 24879984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-alcoholic steatohepatitis].
    Duvnjak M; Virović L
    Acta Med Croatica; 2003; 57(3):189-99. PubMed ID: 14582465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.
    Chalasani N; Deeg MA; Crabb DW
    Am J Gastroenterol; 2004 Aug; 99(8):1497-502. PubMed ID: 15307867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.